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Clinical trials have recently demonstrated the effectiveness of Pre-Exposure Prophylaxis (PrEP) in
preventing HIV infection. Consequently, PrEP may soon be used for epidemic control. We model the
dynamic interactions that will occur between treatment programs and potential PrEP interventions in
resource-constrainedcountries.WedeterminetheconsequencesforHIVtransmissionanddrugresistance.
We use response hypersurface modeling to predict the effect of PrEP on decreasing transmission as a
function of effectiveness, adherence and coverage. We predict PrEP will increase need for second-line
therapies (SLT) for treatment-naı ¨ve individuals, but could significantly decrease need for SLT for
treatment-experienced individuals. If the rollout of PrEP is carefully planned it could increase the
sustainabilityoftreatmentprograms.Ifnot,needforSLTcouldincreaseandthesustainabilityoftreatment
programs could be compromised. Our results show the optimal strategy for rolling out PrEP in
resource-constrained countries is to begin around the ‘‘worst’’ treatment programs.
E
ffectivepreventionstrategiesforcontrollingtheHIVpandemicareurgentlyneeded.Onepotentialstrategy,
currently being investigated in phase III clinical trials, is pre-exposure prophylaxis (PrEP)
1. PrEP is the
administration of low levels of antiretrovirals (ARVs), specifically Tenofovir (TDF) or Truvada (TDF in
combination with emtricitabine (FTC)) prior to HIV exposure
2,3. Results from the first Phase III clinical trial of
oral PrEP, the iPrEx trial, have recently been published
4. The study involved 2,499 men who have sex with men
(MSM) and transgender women who have sex with men from six countries in the Americas, Africa and Asia.
Once-daily oral Truvada was found to reduce the risk of acquiring HIV infection by44% in the study population
overall.Recentresults(currentlyunpublished)fromtwootherclinicaltrialsprovideadditionalevidencePrEPcan
reducerisk.TheTDF2trialinvestigatedtheuseofonce-dailyoralTruvadain1,219heterosexualmenandwomen
in Botswana; the Partners PrEP trial evaluated both TDF and Truvada in 4,758 HIV serodiscordant couples in
Kenya and Uganda. Both studies showed significant reductions in risk of infection ranging from 62% for TDF
(in the Partners PrEP study) to between 63% and 73% for Truvada (in the TDF2 and Partners PrEP studies,
respectively)
5,6. Based on the results from the clinical trials, PrEP may soon be rolled out in resource-constrained
countries as an intervention to reduce heterosexual transmission of HIV. However there is concern this could
generate drug resistance
7, because HIV-infected individuals may inadvertently use PrEP. Drug resistance has
alreadyariseninmanyresource-constrainedcountriesasaconsequenceoftheirHIVtreatmentprograms
8,9.Here
we model the dynamic interactions that will occur between treatment programs and PrEP interventions in
resource-constrained countries. We predict the consequences of these interactions for HIV transmission and
drug resistance. We evaluate both TDF-based and Truvada-based PrEP. The implications of our results for the
rollout of PrEP interventions in Sub-Saharan Africa are discussed.
For user-dependent prevention interventions (e.g., PrEP), phase III clinical trials measure the effectiveness of
the product rather than efficacy
10,11. Effectiveness is a function of the biological efficacy of the product and
participants’ adherence. Effectiveness is a reasonable measure of biological efficacy if adherence is ,100%
11.
The Phase III clinical trials of PrEP (iPrEx, TDF2, and Partners PrEP) all found significant differences in
SUBJECT AREAS:
COMPUTATIONAL
BIOLOGY
DISEASES
BIOLOGICAL MODELS
HIV
Received
12 September 2011
Accepted
23 November 2011
Published
7 December 2011
Correspondence and
requests for materials
should be addressed to
S.B.(sblower@mednet.
ucla.edu)
*Current address:
INSERM U943 Paris &
UPMC Univ-Paris 6,
UMR S943, F75013,
France.
SCIENTIFIC REPORTS | 1 : 185 | DOI: 10.1038/srep00185 1effectiveness depending on participants’ adherence to the study pro-
tocol. In the IPrEx trial, the overall effectiveness of Truvada-based
PrEP was 44% (95% confidence interval (CI): 15 to 63%), but was
extremely dependent upon adherence. PrEP adherence was defined in
terms of the percentage of the daily doses of PrEP that were taken.
Specifically, incidence was reduced by 73% if adherence was high
($90% of doses), 50% if adherence was intermediate ($50% of doses)
and 32% if adherence was low (, 50% of doses)
4. Notably, PrEP was
found to reduce incidence by 92% (95% CI: 40 to 99%) if the regimen
was taken exactly as prescribed
4. No resistance mutations for TDF
were found among iPrEx participants, although three cases of resist-
ance for FTC were found: one in the placebo arm and two in the
Truvada arm. The case in the placebo arm appears to reflect trans-
mitted resistance, and the two individuals whodeveloped mutations in
the Truvada armappear to havebegun PrEP before it was known they
were infected with HIV
4. Based on these results it remains unknown
whether individuals who begin PrEP when they are uninfected, then
fail PrEP and remain on PrEP are likely to develop resistance.
In the TDF2 trial, the effectiveness of Truvada-based PrEP was
63% (95% CI: 22 to 83%)
6. However, among participants known to
have a supply of study drugs, protection was even greater, with an
effectiveness of 78% (95% CI: 41 to 94%). Although some gender
differences were noted, the study was not large enough to draw
definitive conclusions about the effectiveness of Truvada based on
gender. Consistent with the IPrEx trial, there were no cases of drug
resistance among participants taking Truvada who became infected
after enrollment. One case of TDF and FTC resistance occurred in a
participant who had unrecognized HIV infection at the time of
enrollment. In Partners PrEP, the study found 62% (95% CI: 34 to
78%)effectivenessforTDF-basedPrEPand73%(95%CI:49to85%)
for Truvada-based PrEP
5. Both PrEP regimens had similar effective-
ness in men and women. Although it appeared Truvada provided
more protection than TDF alone, this difference was not statistically
significant. Adherence to the daily PrEP medication was very high –
more than 97% of dispensed doses of the study medications were
taken.TwelveparticipantswhohadtestedHIV-negativeatscreening
were found to have acute HIV infection; however information on
drug resistance has not been released yet. Notably, the results of the
PartnersPrEPstudyandTDF2contrast withthoseoftheFEM-PrEP
study, which failed to demonstrate that Truvada-based PrEP was
effectiveinprotectingagainstHIVacquisitionamongat-riskwomen
in Kenya, Tanzania and South Africa
12. In addition, the VOICE trial
of PrEP in heterosexual African women recently discontinued the
daily oral TDF arm and the TDF gel arm, although the oral Truvada
arm of the study is still under way. Currently there are no publicly
availabledatatoexplainwhyTruvadawasnotfoundtobeeffectivein
FEM-PrEP, nor TDF in the VOICE study.
Priortotheclinicaltrialresults,theavailabledataconcerningPrEP
efficacy were mainly from pre-clinical studies of PrEP in the rhesus
macaque model of SHIV/SIV infection
13-17. These studies investi-
gated daily PrEP with TDF or Truvada
13,14,17. Results showed the risk
of simian human immunodeficiency virus (SIV) infection in maca-
quesreceivingdailyPrEPwithTDForTruvadawas3.8-and7.8-fold,
respectively, lower than in untreated macaques
13; indicating PrEP
might significant reduce transmission. Results from another
macaque study
15 suggest PrEP may be less effective in protecting
against infection with drug-resistant viruses than against infection
withwild-typeviruses.Inthatstudylossofprotectiontoinfectionby
TDF-based PrEP was observed in macaques exposed to a SIV isolate
carrying the TDF resistance mutation, K65R
15. Other studies of
macaques have shown resistance can emerge while on PrEP
13,a s
can occur when an individual is receiving ARVs for therapeutic
purposes
18. Since mutations to TDF and FTC acquired during treat-
ment have been observed to rapidly revert when treatment has
stopped
19–21, it is likely that mutations selected while on PrEP will
also revert once the pressure of PrEP is removed. We use the results
from these empirical observations and studies, as well as the recent
results from the Phase III trials, to inform our modeling of PrEP-
based interventions.
Previously we (VS & SB) designed a mathematical model to pre-
dict the effect of PrEP interventions in a ‘‘high-risk’’ community in a
resource-rich country; specifically the MSM community in San
Francisco
22. Our new model is designed to investigate the dynamic
interactions between HIV treatment programs and potential PrEP
interventions in resource-constrained countries. The model tracks
the transmission dynamics of wild-type and resistant strains of
HIV in a generalized epidemic driven by heterosexual transmission.
GeneralizedepidemicsarecharacterizedbyahighprevalenceofHIV
in the general population and occur in many African countries. In
our analyses, PrEP interventions are implemented when treatment
programs are in place, resistant strains are evolving in treated indi-
viduals, and resistant strains are being transmitted. Previous models
of PrEP have been based on unrealistic assumptions. Specifically,
treatment will be unavailable in resource-constrained countries
when PrEP is rolled out
23–26, all infected individuals are eligible for
PrEP
24,26 or neither treatment programs nor PrEP interventions can
generate drug resistance
27.
We use our model to investigate the effect of the ‘‘quality’’ of the
PrEP interventions and the effect of the ‘‘quality’’ of the treatment
programs on transmission and resistance by using uncertainty and
sensitivity analyses (see Methods). We characterize the ‘‘quality’’ of
PrEP interventions in terms of four of the models’ parameters: (i)
coverage (specified by the proportion of sexually active individuals
adopting PrEP each year), (ii) the effectiveness of PrEP for indivi-
duals who are highly adherent to the regimen (defined as taking
$90% of daily doses), (iii) the proportion of individuals who are
highly adherent to PrEP and (iv) the average level of adherence in
individuals who have low/moderate adherence (defined as taking
, 90% of daily doses). We characterize the ‘‘quality’’ of treatment
programs in terms of two of the models’ parameters: (i) the propor-
tion of treated individuals who achieve complete viral suppression
(,400 copies/ml)and(ii)therateofdevelopingresistanceintreated
individuals who only achieve partial viral suppression. Parameter
values used to define the ‘‘quality’’ of PrEP interventions and the
‘‘quality’’ of treatment programs are given in Table S6 and Table
S7 in the Supplementary Material (SM).
Our model includes behavioral heterogeneity with respect to
adherence to PrEP regimens. We define adherence, as in the clinical
trials,intermsofthenumberofdailydosesthataretaken.Wemodel
adherence for each gender independently. We assume a certain pro-
portion of individuals on PrEP are highly adherent (i.e., take $90%
of daily doses) and the remaining proportion on PrEP are low to
moderatelyadherent(i.e.,takelessthan90%ofdailydoses).Wevary
the degree of behavioral heterogeneity in adherence to PrEP regi-
mensbyletting:(i)thesizeofthehighadherencegroupvaryfrom0%
to 100% of the individuals taking PrEP, (ii) the average level of
adherence (in the high adherence group) vary from 90% to 100%
and (iii) the average level of the adherence (in the low/moderately
adherentgroup)varyfromzeroto89%.Ourmodelisdesignedtouse
data from clinical trials; consequently, we model effectiveness of
PrEP rather than efficacy. We model effectiveness as a function of
adherenceandwhetherthestrainiswild-typeorresistant;seeSection
1e and Figure S2 in the SM for technical details. Based on data from
the macaque studies
15 we assume PrEP is less effective against res-
istant strains than against wild-type. We also assume that below a
certain level of adherence there are not enough ARVs present to
protect against infection or to select for resistance. Therefore, when
modelingtheeffectivenessofPrEPandtheriskofdevelopingaDRM
on PrEP, we include an adherence threshold below which effective-
nessisverylowandresistance unlikely. Our modelingofthis thresh-
oldisdescribedindetailinSections1eand1fintheSM,andshownin
Figures S2 and S3 in the SM.
www.nature.com/scientificreports
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vidual has to test negative for HIV. However, none of the currently
available HIV antibody tests can detect infection during the first
few weeks after infection (i.e., during the ‘‘window period’’)
28,29.I n
Botswana, HIV testing is by parallel rapid tests or parallel ELISAs: in
the first case, Uni-Gold Recombigen HIV (Trinity Biotech, Bray,
Ireland) and Determine HIV 1/2 (Abbott Diagnostics, Abbott Park,
IL) tests are used. If the results are discordant, then parallel tests are
repeated.Iftherapid testsare still discordant, the OraQuick (OraSure
Technologies, Bethlehem, PA) test is used as a tie-breaker
30.T h e s e
tests have shown very high sensitivity and specificity (,100%) in
Botswana in detecting HIV in individuals whose infection is outside
the ‘‘window period’’
31,32. Consequently, when modeling PrEP inter-
ventions we assume tests are 100% accurate in detecting HIV when
testingoccursafterthe ‘‘windowperiod’’and donotdetectHIVwhen
testing occurs during the ‘‘window period’’. Hence in our analyses,
recentlyinfectedindividualstestedduringthe‘‘windowperiod’’could
inadvertently be prescribed PrEP, but infected individuals tested after
the ‘‘window period’’ would not be prescribed PrEP. The Center for
Disease Control and Prevention in the United States recommends
that individuals who take PrEP should be tested every three months
to check whether they have become infected. Testing frequency in
resource-constrained countries is unlikely to be more frequent than
in the US. Therefore in our analyses we explored a range of testing
frequencies varying from every three months to every six months.
Our model includes two mechanisms for selecting for a drug-
resistant mutation (DRM) on PrEP. A DRM can be selected if (i)
an HIV-infected individual in the ‘‘window period’’ of infection
inadvertently begins taking PrEP or (ii) an individual acquires infec-
tion when they are on PrEP and then remains on the regimen. We
model the risk of an individual developing a DRM on PrEP as a
function of: their level of adherence to the regimen, their stage of
HIV infection (primary or chronic), the specific PrEP regimen they
take (TDF-based or Truvada-based) and the time they spend on
PrEP once infected with HIV; see Section 1f and Figure S3 in the
SM for technical details. As well as modeling the emergence of res-
istant strains due to the selective pressure of PrEP, we model the
emergence of resistant strains in treated individuals taking first-line
therapies.Wealsomodelreversionofresistantstrainstowild-typein
infected individuals who: i) develop resistance while on PrEP and then
come off PrEP or ii) acquire transmitted resistance. Reversion occurs
because wild-type strains out-compete the resistant strains in the
absence of ARVs. In addition, we model (after reversion has occurred)
the reemergence of resistant strains under the selective pressure of
treatment. Resistance can reemerge quickly as resistant strains are
maintained in reservoirs as minority strains within the individual.
For the technical details of our modeling of resistance see SM.
We investigate the two PrEP regimens that are currently being
investigated in clinical trials: TDF and Truvada. A full listing of
PrEP trials is given in Table 1. In our modeling of the evolution of
resistance on TDF-based PrEP, we model the DRM that has been
observedtobeselectedforbyTDF,K56R.InouranalysisofTruvada-
based PrEP we model the risk of developing M184V. In infected
humans and non-human primates taking Truvada, the first DRM
that has generally been observed is M184V; K65R has been observed
to arise subsequently, if the infected primate or human remains on
Truvada
7. We do not model the possibility of further selection for
K65Rbecauseweincludefrequenttestinginourmodel.Ifindividuals
on PrEP, in our model, are found to be infected with HIV they will
notbegivenfurtherPrEPregimens.Iftestingisfrequent,itisunlikely
that an HIV-infected individual would remain on PrEP long enough
to select both M184V and K65R. We note that in the iPrEx trial
(where trial participants were tested approximately monthly) it
was found that among HIV-infected individuals on Truvada-based
PrEP only M184V was selected
4; the virus did not evolve further and
acquire K65R. In TDF2, there was one case of a participant who
started taking Truvada while having acute HIV infection and had
several false negative HIV tests in the months following enrollment
6.
The individual tested positive for K65R and M184V, and also had a
broad-spectrum NNRTI mutation A62V, which suggests that the
virus they had contracted was not wild-type. One seroconverter in
the placebo arm was also found to have low levels of K65R. We note
that the complexity of our model could be increased to include the
sequential evolution of multiple DRMs.
TheGovernmentofBotswanaisconsideringimplementingpublic
health interventions based on PrEP if several of the Phase III trials
demonstrate effectiveness, PrEP is shown to be cost effective and the
healthsystemisabletodeliversuchservices.Botswanahasoneofthe
Table 1 | Ongoing and Planned daily oral PrEP Trials
1
Location Sponsor/Founder Population PrEP strategies being tested Status/Results expected
Phases III, IIb (safety and effectiveness)
Kenya, South Africa, Tanzania,
Zimbabwe (FEM-PrEP)
BMGF, FHI, USAID 3,900 heterosexual women Daily oral TDF/FTC Data Analysis/TBD
a
Uganda, Kenya (Partners PrEP) BMGF 4758 serodiscordant
heterosexual couples
Daily oral TDF; daily oral
TDF/FTC
Data Analysis/TBD
b
Thailand (CDC 4370) CDC 2,400 injecting drug users Daily oral TDF Fully enrolled/Q1
2012
South Africa, Uganda,
Zimbabwe (VOICE MTN 003)
NIH/MTN 5,000 heterosexual women Daily oral TDF;daily oral
TDF/FTC;daily TDF gel
Fully enrolled
c/Q1
2013
Phases I, II (safety, adherence, acceptability, feasibility)
Botswana (TDF2; CDC 4940) CDC 1,200 heterosexual
men & women
Daily oral TDF/FTC Data Analysis/TBD
United States HPTN069 HPTN, NIH 400 MSM MVC; MVC1FTC;
MVC1TDF; TDF/FTC
in development
Uganda (IAVI E002) IAVI 72 heterosexual men & women Daily and intermittent TDF/FTC Ongoing/TBD
Open Label
Peru, Ecuador, US, South Africa,
Brazil, Thailand (iPrEx OLE)
NIH iPrEx and ATN 082 participants
offered opportunity to enroll in
open-label extension
Daily oral TDF/FTC Enrolling/2013
DAIDS:DivisionofAcquiredImmunodeficiencySyndrome;BMGF:Bill&MelindaGatesFoundation;CDC:USCentersforDiseaseControl;MTN:MicrobicideTrialsNetwork;NIH:USNationalInstitutesof
Health; MSM: Men who have Sex with Men; IAVI: International AIDS Vaccine Initiative; ATN: Adolescent Trial Network; USAID – United States Agency for International Development; FHI – Family Health
International; TDF: TDF; FTC: emtricitabine; MVC: maraviroc; TBD: To be determined.
astopped early due to futility.
bstopped early for efficacy of Truvada and TDF.
coral TDF and TDF gel arms stopped early.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 185 | DOI: 10.1038/srep00185 3highest levels of HIV in the world. The most recent World Health
Organization report
33 and the Botswana AIDS Impact Survey
34 indi-
cate that: (i) ,30% of women (aged 15–49 years) and ,20% of men
(aged 15–49 years) are infected with HIV, (ii) HIV incidence is high,
,4.4% in women and ,2.5% in men
34 and (iii) transmitted drug
resistance has reached ,4%
35. Botswana is a relatively rich country
withoneofthebesthealthcaresystemsinAfricaand,potentially,has
the resources available to provide PrEP to the general population. In
addition, the population size is small, only ,1 million adults aged
between 15 and 49 years old, live in Botswana. Therefore, it is a
feasible strategy for the entire population to be offered PrEP. In
addition, since it has the highest HIV treatment coverage of any
African country it may now be able to afford to concentrate on
prevention. In 2002 it was the first African country to offer free
ARVstoeveryoneinneedoftreatment;treatment wasrapidly scaled
up and now 70–80% of those in need are receiving ARVs
36,37.
Treatment programs in Botswana have been very successful; a
studyofthefirst5yearsoftreatmentfoundthepercentageofpatients
with viral loads less than 400 copies/ml at one, three and five years
was 91%, 90% and 98%, respectively
38. However some patients on
first-line regimens are now virologically failing treatment and devel-
oping resistance to TDF
39, although the number of patients needing
second-linetherapies(SLT)iscurrentlylow
35.InBotswana,aswellas
inmany other Sub-Saharan African countries, the potential problem
ofPrEPincreasingresistanceisofparticularconcernsincetheirfirst-
line treatment regimens are based on TDF
40. For example, Atripla
(efavirenz/FTC/TDF) has been used, since 2008, as the first-line
treatmentregimeninBotswana.AriseinTDF-resistancecouldchal-
lenge future treatment options and potentially increase the need for
SLT regimens in Botswana, as well as could occur in other countries
in Sub-Saharan Africa. We use our model to investigate the conse-
quences, for HIV transmission and drug resistance, of the dynamic
interactions between potential PrEP interventions and current treat-
ment programs in Botswana.
Results
Model validation. To assess the validity of our model we began the
simulations of our model in 2002 when the rollout of treatment
began in Botswana. We then assessed the goodness of fit of the
model by comparing its outputs (for 2010) against current empiri-
cal data from Botswana. Specifically, we compared the outputs
against seven epidemiological measures of the current HIV epide-
mic. The model outputs are an excellent fit to current empirical data
from Botswana; see Table S9 in the SM. For example, the model
predicts: (i) HIV prevalence in women is 32% (compared with
actual prevalence of ,30%), (ii) HIV prevalence in men is 23%
(compared with actual prevalence of ,20%), (iii) HIV incidence in
women is 4.5% (compared with actual incidence of ,4.4%) and (iv)
HIV incidence in men is 2.7% (compared with actual incidence of
,2.5%). This goodness-of-fit analysis demonstrates that our model
isavalidrepresentationofthecurrenttransmissiondynamicsofHIV
in Botswana in the presence of their treatment programs and pre-
PrEP interventions.
Predictionsfromtheuncertaintyanalysis:incidence&prevalence.
Figure 1 shows model predictions for Botswana obtained from
three uncertainty analyses (see Methods). Each of the three sets of
predictions are based on different conditions: (i) only current treat-
ment programs and no PrEP interventions, (ii) current treatment
programs plus the introduction of TDF-based PrEP interventions,
and (iii) current treatment programs plus the introduction of
Truvada-based PrEP interventions. Ten year predictions are shown
for incidence in women (Figure 1A), prevalence in women
(Figure 1B), incidence in men (Figure 1C), and prevalence in men
(Figure 1D).
The model predicts that even without PrEP interventions, incid-
enceandprevalencewilldecreaseslightlyoverthenextdecadedueto
the effect of the current treatment programs on reducing infectivity
of treated individuals (Figure 1). If PrEP interventions are imple-
mented in Botswana, along with the current treatment programs,
incidence and prevalence could decrease significantly; irrespective
ofwhethertheinterventionsarebasedonTDForTruvada(Figure1).
If Truvada-based PrEP interventions are implemented, incidence
could drop from 4.5% (median; IQR 3.2%–6.1%) to 1.6% (median;
IQR 1.1%–2.4%) in women and from 2.7% (median; IQR 1.9%–
3.8%) to 1.0% (median; IQR 0.7%–1.6%) in men; very similar results
were found for TDF-based PrEP interventions (Figure 1). Notably,
these reductions in incidence (i.e., reductions in transmission) and
prevalence are due to both the PrEP interventions and the treatment
programs. As the incidence falls, prevalence decreases. If Truvada-
based PrEP interventions are implemented, prevalence could
decrease from 32% (median; IQR 26%-39%) to 20% (median; IQR
15%–25%)inwomenandfrom23%(median;IQR17%–29%)to14%
(median; IQR 10%–18%) in men; very similar results were found for
TDF-based PrEP interventions (Figure 1).
OurmodelingshowsthattheintroductionofTruvada-basedPrEP
interventions, over a decade, could prevent 39% (median; IQR 29%–
49%) of new infections in women and 40% (median; IQR 30%–50%)
of new infections in men in Botswana. Predictions for the number of
infections prevented are not significantly different for TDF-based
PrEP versus Truvada-based PrEP.
Key parameters in reducing transmission. To determine which
parameters were most important in decreasing transmission (i.e.,
the key parameters) we conducted two types of sensitivity analyses.
One was based on calculating Partial Rank Correlation Coefficients
(PRCCs), the other based calculating Standardized Regression
Coefficients (SRCs) and response hypersurface modeling
41; see
Methods. We defined key parameters as those with a PRCC greater
than 0.4 or less than minus 0.4. Both types of sensitivity analyses
identify the key parameters; however the results from response
hypersurface modeling provide additional insights. Three dimen-
sional response hypersurfaces were generated by using multivariate
analysis toidentify linear and nonlinear relationships among the key
parameters. Each color-coded plot of a response hypersurface shows
the predictions from the model for one specified outcome variable
(Z) as a function of two of the models’ key parameters (Y1 and X1);
where Z 5 a1Y1 1 a2X1 1 a3Y1X1 and a1, a2 and a3 specify the
coefficients in the regression equation. The interaction effect
between the two key parameters is shown by the curvature of the
hypersurface.
The key parameters which affect transmission, after the introduc-
tionofPrEPinterventionsinthepresenceoftreatmentprograms,are
shown in bold in Table 2 and Table S10 in the SM. There are no
significant differences between TDF-based PrEP and Truvada-based
PrEP with respect to their values of PRCCs or their SRCs. Not sur-
prising,thekeyparameters indetermining thesuccessofPrEPinter-
ventions in reducing transmission are the parameters that specify
adherence, coverage and the effectiveness of PrEP for women who
are highly adherent to the regimen (Table 2). The response hyper-
surfaces in Figure 2 reveal the independent and interaction effects of
these key parameters on the percentage of infections prevented in
women 10 years after Truvada-based PrEP interventions have been
introduced. Plots are color-coded based on the predicted degree of
reductionintransmission;regressionequationsusedtoconstructthe
hypersurfaces are given in the Figure Legend. The introduction of
PrEP interventions could have very little effect on reducing trans-
mission (shown by the dark blue region) or a substantial effect
(,55%) on reducing transmission (shown by the dark red region)
or anywhere in between (Figure 2). Figure S4 in the SM shows re-
sults for Truvada-based PrEP interventions for men. Results for
www.nature.com/scientificreports
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results for men are shown in Figure S5 in the SM.
Figure 2A shows the effect of any specific PrEP intervention on
reducing transmission as a function of the effectiveness of the regi-
men for women who are highly adherent (see Y-axis) and coverage
(i.e., the proportion of sexually active women who adopt PrEP each
year)(seeX-axis).Figure2BshowstheeffectofthePrEPintervention
on reducing transmission as a function of the adherence level of
women specified in terms of: (i) the proportion of women who are
highlyadherent(seeY-axis)and(ii)theaveragelevelofadherencein
women who have low/moderate adherence (see X-axis). The curv-
ature of the hypersurface shows there is a strong interaction effect
between these two key adherence parameters. Notably, Figure 2B
showsawidevarietyofadherencepatternscouldcausesimilarreduc-
tionsintransmission.Forexample,transmissioncouldbereducedby
,40% if ,70% of the women taking Truvada-based PrEP are highly
adherent (i.e., take $90% of daily doses) and the other women have
extremely low adherence (i.e., on average take ,10% of daily doses).
Transmissioncouldalsobereducedby,40%,if,40%ofthewomen
are highly adherent (i.e., take $90% of daily doses) and the other
women are only moderately adherent (i.e., on average take ,60% of
daily doses).
Change in need for Second-Line Therapies (SLT) for treatment-
naı ¨ve individuals. Our results from the uncertainty analyses show
thenumberoftreatment-naiveindividualsinneedofSLTisverylikely
to increase in the decade after implementing PrEP interventions;
this occurred in 99% of the 937 simulations conducted for the
uncertainty analyses. The result is regardless of whether the PrEP
regimen was based on TDF or Truvada. Our sensitivity analyses
show only one parameter is important in determining the degree
of increase in need (Table 2). This key parameter reflects the
‘‘quality’’ of the PrEP intervention; specifically, the average level of
adherence in individuals who have low/moderate adherence to the
regimen. The sensitivity of the results to this parameter is similar for
TDF-basedPrEP and Truvada-based PrEP (Table2 and Table S10 in
the SM).
The predictions of the model showing the increase in the number
of treatment-naive women in need of SLT (shown in Figure 3A for
TDF-basedPrEPandinFigure3BforTruvada-basedPrEP),afterthe
introduction of PrEP interventions, is shown in terms of a ratio (see
Methods). Corresponding results for treatment-naı ¨ve men are
shown in Figures S6A and S6B in the SM. Each prediction shown
in Figure 3 is from one of the 937 simulations conducted for the two
uncertainty analyses where PrEP interventions were introduced
when treatment programs were in place. Results are stratified based
on whether the average level of adherence for the group of women
who take , 90% of daily doses was low (,40%; shown by the blue
bars) or moderate to high (between 40% and 89%; shown by the red
bars).Ifadherence waslow,theincrease inthenumberoftreatment-
naive women in need of SLT was ,50% (Figure 3). When Truvada-
based PrEP interventions were simulated (Figure 3A) the increase
in need was slightly less than when TDF-based PrEP interventions
were simulated (Figure 3B). Specifically, the SLT need ratio was 1.4
Figure 1 | Model predictions from the uncertainty analysis for women in Botswana for 10 years from when Truvada-based PrEP interventions
are introduced: (a) HIV incidence and (b) HIV prevalence. Bars with black stripes show the values of HIV incidence in (a) and prevalence in (b) in
women before the introduction of PrEP-based interventions. Model predictions are shown for the following conditions: treatment only (black bars),
treatment plus Tenofovir-based PrEP (grey bars) and treatment plus Truvada-based PrEP (white bars). (c) same as (a) but for men. (d) same as (b) but
for men.
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theaveragelevelofadherencewasbetween40%and89%thenumber
of treatment-naive women in need of SLT could more than double
aftertheintroductionofPrEPinterventions.Again,ifTruvada-based
PrEP was used the increase in the SLT need ratio was less than when
TDF-based PrEP was used; 2.5 (median; IQR 1.9–3.7) versus 3.0
(median; IQR 2.3–4.5).
Change in need for Second-Line Therapies for treatment-
experienced individuals. In contrast to our results for treat-
ment-naı ¨ve individuals, our results show the number of treatment-
experienced individuals in need of SLT is very likely to decrease in
the decade after implementing PrEP interventions. This occurred
in 927 of the 937 simulations conducted for the two uncertainty
analyses where PrEP interventions were introduced when treatment
programs were in place. The result is regardless of whether the
regimen was based on TDF or Truvada. Our sensitivity analyses
identified five key parameters that determined the decrease in need
for SLT by treatment-experienced individuals; three parameters
characterize the ‘‘quality’’ of PrEP interventions and two para-
meters characterize the ‘‘quality’’ of the treatment programs
(Table 2 and S10 in the SM).
The three key parameters characterizing the ‘‘quality’’ of PrEP
interventions were: (i) coverage (in terms of the proportion of sexu-
allyactiveindividualswhoadoptPrEPeachyear),(ii)theproportion
of individuals taking PrEP who are highly adherent (i.e., who
take $90% of daily doses) and (iii) the average level of adherence
in individuals who have low/moderate adherence (i.e., who take
, 90% of daily doses). Taken together these parameters determine
the ‘‘quality’’ of PrEP interventions in terms of their effectiveness
in reducing transmission. The more effective the PrEP intervention
in reducing transmission, (i.e., the higher the ‘‘quality’’ of a PrEP
intervention) the greater the expected reduction in the number of
treatment-experienced women in need of SLT (Partial Correlation
Coefficient(PCC)520.76)(Figure4A).Decreases inneedcouldbe
fairly substantial, up to a ,25% reduction (Figure 4A). Corres-
ponding results for men and Truvada-based PrEP are shown in
Figure S7A in the SM; results for TDF-based PrEP in Figure S7B
(for women) and Figure S7C (for men).
The two key parameters characterizing the ‘‘quality’’ of treatment
programs were: (i) theproportion of treated individuals who achieve
complete viral suppression (,400 copies/ml) and (ii) the rate of
developing resistance in treated individuals who only achieve par-
tial viral suppression. Our sensitivity analyses show the greatest
decreases in the number of treatment-experienced individuals in
need of SLT will occur in treatment programs that currently are of
low ‘‘quality’’. Specifically, programs that have a high percentage of
patients who are only partially virally suppressed and a high rate of
developing resistance in treated individuals who only achieve partial
viral suppression (Table 2 and S10 in the SM).
Taken together our modeling results show a dynamic interaction
between treatment programs and PrEP interventions will determine
the magnitude of decrease in the number of treatment-experienced
individualsinneedofSLT.Theeffectsofthisinteractionbetweenthe
‘‘quality’’ ofthePrEP intervention andthe ‘‘quality’’of thetreatment
program is shown in the form of a response hypersurface in
Figure4B;thishypersurfaceshowstheinteractionbetweentreatment
programs and Truvada-based PrEP interventions on decreasing the
need for SLT for treatment-experienced women. Corresponding
results for men and Truvada-based PrEP are shown in Figure S7D
in the SM; results for TDF-based PrEP in Figure S7E (for women)
and Figure S7F (for men). The color-coded response hypersurface
in Figure 4B shows the ratio of need decreases as the proportion of
women on PrEP who are highly adherent (shown on the Y-axis)
increases and/or the proportion of individuals who are virally sup-
pressedontreatmentdecreases(shownontheX-axis).Theinteraction
effect between these two key parameters is shown by the curvature
of the hypersurface; the regression equation used to construct the
hypersurface is given in the Figure Legend. These results show the
greatest decrease in number of treatment-experienced individuals in
Table 2 | Table of Partial Rank Correlation Coefficients (PRCCs) for key experimental parameters identified in the sensitivity analysis of the
two PrEP regimens studied: Tenofovir-based PrEP (TDF) and Truvada-based PrEP (TDF1FTC). PRCCs for men and women were calculated
separately; values for men are shown in ()’s. IP: % of cumulative infections prevented; SLTN: ratio of need for second-line therapies for
treatment-naı ¨ve individuals; SLTE: ratio of need for second-line therapies for treatment-experienced individuals
Model outcome variables
IP SLTN SLTE
TDF TDF1FTC TDF TDF1FTC TDF TDF1FTC
Proportion (average) of sexually active men
who are tested HIV-negative and adopt PrEP each
year (proxy for coverage)
0.27
(0.57)
0.22
(0.56)
20.02
(0.30)
0.02
(0.28)
20.21
(20.59)
20.22
(20.50)
Proportion (average) of sexually active women who
are tested HIV-negative and adopt PrEP each year
(proxy for coverage)
0.56
(0.25)
0.57
(0.25)
0.24
(20.10)
0.21
(20.09)
20.65
(20.26)
20.62
(20.37)
Proportion of women highly adherent to PrEP 0.80
(0.38)
0.80
(0.39)
20.02
(20.09)
20.06
(20.12)
20.73
(20.22)
20.77
(20.26)
Proportion of men highly adherent to PrEP 0.43
(0.82)
0.44
(0.82)
20.05
(0.00)
20.08
(0.00)
20.27
(20.74)
20.28
(20.79)
Level of PrEP adherence among partially
adherent men
0.30
(0.66)
0.23
(0.65)
20.01
(0.56)
0.04
(0.54)
20.21
(20.64)
20.17
(20.55)
Level of PrEP adherence among partially
adherent women
0.69
(0.27)
0.69
(0.25)
0.59
(0.01)
0.56
(0.05)
20.66
(20.15)
20.62
(20.20)
Effectiveness of PrEP against wild-type strains among
individuals who are highly adherent
0.42
(0.43)
0.44
(0.44)
20.30
(20.31)
20.32
(20.32)
20.36
(20.27)
20.39
(20.39)
Proportion of individuals who are virally
suppressed on treatment
0.12
(0.10)
0.10
(0.09)
0.33
(0.35)
0.34
(0.37)
0.67
(0.63)
0.64
(0.64)
Proportion of individuals only partially virally
suppressed on treatment who develop
resistance on treatment per year
0.02
(0.05)
0.02
(20.05)
20.26
(20.23)
20.61
(20.53)
20.61
(20.53)
20.59
(20.54)
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out around the ‘‘worst’’ treatment programs.
Notably, wefindthat thereisno correlation betweenchanging the
need for SLT for treatment-naı ¨ve individuals and changing the need
for treatment-experienced individuals (PCC 5 0.20).
Discussion
In our comparison of TDF and Truvada-based PrEP we found both
regimenswouldleadtoanincreaseinthenumberoftreatment-naı ¨ve
individuals infected with resistant strains. Regardless of the level of
adherence to the regimen, we found the increase would be greater if
TDF-based PrEP was used than if Truvada-based PrEP was used.
Our results indicate that Truvada-based PrEP would be a more
optimal regimen. In addition, the specific mutations that arise will
influence subsequent treatment and therefore need to be considered
whenchoosing between regimens; K65Rwill beselected byTDF and
M184V by Truvada. K65R may limit the utility of TDF in combina-
tion therapy for a newly infected individual. This may lead to greater
use of alternative agents such as zidovudine with variable costs, tox-
icities and effectiveness. If K65R limits TDF effectiveness then the
convenience of TDF co-formulated products may be lostand the use
of more complex regimens with more pills or multiple daily admin-
istrations may be required; this might influence medication adher-
ence.Inaddition,awidelyspreadK65RmutationwouldlimitTDFas
aneffectiveagentforPrEP.M184Vmayhavelesssubsequentclinical
impactonthe useof co-formulatedpillsforthetreatment ofinfected
individuals or for the need for alternative treatment regimens. Thus
theimplicationsofour modelingsuggest thatTruvada-basedPrEPif
well tolerated and affordable would be the more optimal regimen, as
it would cause less clinical complexities than TDF-based PrEP.
In a previous modeling study, we (VS & SB) found that if PrEP is
widely used in a ‘‘high-risk’’ community in San Francisco (i.e., in a
resource-rich country) the number of treatment-naı ¨ve individuals
infected with resistant strains is likely to decrease (if risk behavior
does not increase). In contrast, in this study we have found that after
the introduction of PrEP interventions in Botswana, the number of
Figure 2 | Sensitivity analysis results, presented as response
hypersurfaces,derivedfrom theresults,10yearsafter theintroductionof
a Truvada-based PrEP intervention, of the uncertainty analysis. Color-
coded response hypersurfaces show the percentage ofinfections prevented
inwomen inBotswana (Z)asafunction of: (a)the effectiveness ofPrEP in
protecting women who are highly adherent to PrEP against infection with
wild-typestrainsofHIV(Y1) andtheproportion ofsexuallyactive women
whoadoptPrEPeachyear(X1)(Z50.24Y110.32X110.04Y1X1),(b)the
proportion of women on PrEP who are highly adherent (Y2) and the level
of PrEP adherence among women who are only partially adherent (X2),
(Z 5 0.62Y2 1 0.41X2 2 0.26Y2X2).
Figure 3 | Histogram of the number of simulations from the uncertainty
analysis showing values for the ratio of need for second-line therapies
(SLT)fortreatment-naı ¨vewomenwhenPrEPinterventionsarebasedon:
(a) Tenofovir or (b) Truvada. Blue bars represent values when the level of
adherence to PrEP is less than 40% among women with only moderate
adherence;redbarsrepresent valueswhenthelevelofadherencetoPrEPis
between 40% and 89% among the women who are only moderately
adherent.
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increase.Thisoccursbecausethelevelofambientresistanceishigher
in San Francisco than in Botswana due to a longer treatment history.
This comparison of results indicates that the impact of PrEP on
transmitted resistance will be highly dependent on the number of
years since treatment was first made available, as well as the current
success of treatment programs. Consequently the impact of PrEP
interventions on transmitted resistance may be beneficial in resource-
rich countries, but detrimental in resource-constrained countries.
In this study, we have presented a novel mathematical model
designedtopredicttheimpactofPrEPinterventionsintroducedinto
resource-constrained countries with generalized HIV epidemics and
treatment programs already in place. We have parameterized our
model using country-specific data in order to make predictions for
the impact of PrEP interventions on transmission and resistance in
Botswana. The response hypersurfaces that we have constructed can
be used for policy and planning purposes by health officials in
Botswana to predict the effect of TDF-based or Truvada-based
Figure 4 | Model predictions from the uncertainty analysis after ten years of Truvada-based PrEP. (a) Scatterplot of the percentage of infections
preventedinwomenversustheratioofneedforsecond-linetherapies(SLT)fortreatment-experienced women.(b)Sensitivityanalysisresults,presented
as response hypersurfaces, derived from the results of the uncertainty analysis. Color-coded response hypersurface shows the ratio of need for SLT for
treatment-experiencedwomen(Z)asafunctionoftheproportionofwomenonPrEPwhoarehighlyadherent(Y1)andtheproportionofindividualswho
are virally suppressed on treatment (X1); (Z 52 0.52 Y1 1 0.35 X1 1 0.08 Y1X1).
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effectiveness, adherence and coverage. Health officials can also use
the model predictions to determine the number of SLT that will be
needed by specific treatment programs. Our model can be repara-
meterized and used to make predictions for other countries in sub-
Saharan Africa that have generalized HIV epidemics and treatment
programs. Reparameterization of the model will enable country-
specific response hypersurfaces to be constructed and for country-
specific predictions to be made regarding changing needs for SLT.
Therefore our model could be used as an important policy and
planning tool in many resource-constrained countries. Although
quantitative results will be country-specific, the qualitative insights
we have gained regarding the impact of interactions between treat-
ment programs and PrEP interventions will hold for other resource-
constrained countries with generalized epidemics.
Our modeling shows it is essential to consider the dynamic
interaction that will occur between treatment programs and PrEP
interventions. The outcome of this interaction has significant impli-
cations for the success of PrEP interventions and the sustainability
of treatment programs. We have found ‘‘high quality’’ PrEP inter-
ventions will substantially reduce the number of treatment-naı ¨ve
individualsinneedoffirst-linetherapiesandcouldalsosubstantially
reduce the number of treatment-experienced individuals in need of
SLT. Hence ‘‘high quality’’ PrEP interventions are likely to reduce treat-
ment costs which would contribute to the sustainability of treatment
programs. However, if PrEP interventions are not ‘‘high quality’’ (for
example, if - on average - individuals on PrEP only take between 40%
and 89% of daily doses) the number of treatment-naı ¨ve individuals in
needofSLTcould significantlyincrease;evenifindividualstakingPrEP
are frequently tested. Consequently poor ‘‘quality’’ PrEP interventions
could reduce the success of current treatment programs. Our response
hypersurface modeling shows PrEP interventions could prevent the
same number of HIV infections whether behavior is very heterogen-
eous with respect to adherence (i.e., the majority of individuals are
extremely adherent and the minority have very low adherence) or fairly
homogeneous (i.e., all individuals are moderately adherent; none have
extremely high, or low, adherence). These results indicate it will be
difficult to assess the ‘‘quality’’ of PrEP interventions in terms of their
effectiveness in reducing transmission by monitoring adherence.
Notably, our results indicate the most beneficial rollout strategy
would be to begin introducing high ‘‘quality’’ PrEP interventions
around poor ‘‘quality’’ treatment programs (i.e., programs with
low success in viral suppression and high rates of acquired resist-
ance). This rollout strategy would maximize the reduction in the
number of treatment-experienced individuals in need of SLT. In
summary our analysis shows that if the rollout of PrEP is carefully
planned it could decrease the need for SLT and increase the sustain-
ability of treatment programs. If it is not, the need for SLT could
increase and the sustainability of treatment programs in resource-
constrained countries could be compromised.
Methods
Before implementing PrEP interventions we modeled the rollout of HIV treatment
based on empirical data of the numbers of patients that were treated each year in
Botswana; we used empirical data beginning in 2002 when the roll-out began in
Botswana
36,37. After calibrating/validating our model we evaluated both TDF-based
and Truvada-based PrEP interventions.
Figure 5 | Simplified flow diagram of the PrEP model for women. The model includes both current treatment programs and the implementation of
potential PrEP interventions. A full description of the flow-diagram is given in the Methods section. The equations that specify the model are given in
Section 1 of the Supplementary Material.
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33 for women and 33 for men; equations are given in Section 1a in the SM. A
simplified schema of the model is shown in Figure 5 for women; the corresponding
schema for men is shown in Figure S1 in the SM. In Figure 5 women with high
adherence to PrEP are represented by the dark purple rectangle and the two dark
purple squares, women with low/moderate adherence to PrEP are represented by the
light purple rectangle and the two light purple squares, and women not taking PrEP
are represented by the white rectangle and white squares. The four rectangles
represent uninfected women, and squares represent HIV-infected women.
Uninfected women can go on or off PrEP, as shown by the grey arrows. We assume
PrEP will reduce, but not eliminate, the risk of infection. Consequently, whether or
notawomanistakingPrEPshecanbecomeinfectedwithwild-typestrains(shownby
bluearrows)orresistantstrains(shownbyredarrows).HIV-infectedwomenwhoare
taking PrEP are at risk of developing resistance (shown by the orange arrows) until
they either give up PrEP (shown by the grey arrows) or are retested when they try to
renew their prescription, whichever occurs first. Resistant strains that are selected
whenon PrEPcanrevert towild-typestrainswhen off PrEP,reversion can alsooccur
in individuals with transmitted resistance (shown by the turquoise arrows). These
resistant strains remain as minority strains and can reemerge when the infected
individual goes on treatment (shown by the brown arrow). The model also allows for
the development of resistance in treated individuals infected with wild-type strains
(shownbybrownarrow).ThemodelisdescribedingreatertechnicaldetailinSection
1 of the SM.
Quantifying the need for Second-Line Therapies. To determine whether
introducing PrEP could change the need for SLT we calculated a ratio: the number of
individualsthatwouldneedSLTifPrEPwasmadeavailabledividedbythenumberof
individuals that would need SLT if PrEP was not available. A ratio . 1 indicates the
introductionofPrEPinterventionswouldincreasethenumberofindividualsneeding
SLT and a ratio , 1 indicates that it would decrease the number of individuals
needing SLT. The SLT need ratio was calculated both for TDF-based PrEP and
Truvada-based PrEP; for each regimen the ratio was calculated separately for
treatment-naı ¨ve individuals and treatment-experienced individuals. Treatment-
naive individuals who need SLT are either individuals who were infected with
resistant strains through transmission or individuals who acquired resistance when
taking PrEP. Treatment-experienced individuals in need of SLT are individuals that
acquired resistance during treatment with first-line regimens.
Parameterization. We parameterized our model using demographic and behavioral
data from Botswana (Table S1 in the SM). We used data from the Demographic
Health Survey conducted in Botswana
34,42; in this survey they collected demographic
andbehavioraldatainatwostagestratifiedsamplingschemeandthenweightedthese
data to ensure that the survey participants adequately represented the general
population in Botswana. We also used data from Botswana to model their current
treatment programs and treatment regimens in terms of viral suppression rates and
ratesof acquiring resistance on treatment;seeSection 1hin theSM, parameter values
are given in Table S2. The parameter values that we used to define the ‘‘quality’’ of
PrEP interventions are given in Table S6 and Table S7.
In the model, all individuals who become infected with HIV pass through the
followingstages:(i)acuteinfection,(ii)infectedbutnotyeteligiblefortreatment(i.e.,
CD4 count . 200 cells/microL) and (iii) eligible for treatment (i.e., CD4 count #200
cells/microL). After passing through these three stages individuals can go on treat-
ment;parametersspecifyingtimespentineachstageisgiveninTableS3intheSM.In
the different stages of infection, and when on treatment, we assume different viral
loads;seeTableS4intheSM.Weuseviralloadstocalculateinfectivity;seeSection1d
and Table S5 in the SM. We assume that a reduced viral load translates into reduced
infectiousness
43 and hence reduces the transmissibility of HIV
44–48.
We discuss our assumptions in modeling TDF-based and Truvada-based PrEP
regimens with respect to M184V and K65R in Section 1g in the SM; regimen-specific
parameter values are given in Table S7 in the SM.
Model Calibration/validation. Before modeling the interaction between treatment
programs and PrEP interventions we calibrated/validated the model using Monte
Carlo filtering and fitted the model to empirical data from Botswana; see Section 2 in
theSMfordetails,andTableS9andFigureS8.Thisprocedureresultedinreducingan
initial sample of 10,000 simulations, obtained through Latin Hypercube Sampling
49,
to 937 simulations. We used these 937 simulations to conduct a series of uncertainty
and sensitivity analyses
41,49.
Uncertainty Analyses. To conduct uncertainty and sensitivity analyses we treated all
of the PrEP-related parameters in the model as experimental variables. Experimental
variables were either PrEP program-level parameters (Table S6) or parameters that
define the biological characteristics of PrEP regimens (Table S7). Together these
parameters characterize the ‘‘quality’’ of a PrEP intervention. We also used
parameters specifying the ‘‘quality’’ of treatment parameters as experimental
variables. We modeled both TDF-based and Truvada-based PrEP interventions;
differences between the two regimens are discussed in Section 1g and regimen-
specific parameter values are given in Table S7.
We conducted three uncertainty analyses, each based on the 937 simulations
obtained after calibrating the model to current epidemiological data from Botswana.
InthefirstwemodeledcurrenttreatmentprogramsinBotswanawithoutintroducing
PrEP interventions. In the second we modeled current treatment programs and
TDF-based PrEP interventions. In the third we modeled currenttreatment programs
and Truvada-based PrEP interventions. We used the results from these analyses to
comparetheepidemiologicalimpactofTDF-basedPrEPversusTruvada-basedPrEP.
See Section 3 in the SM for further details of these uncertainty analyses.
Sensitivity analyses. We conducted two types of sensitivity analyses: one based on
calculatingPRCCsandtheotherbasedoncalculatingSRCandresponsehypersurface
modeling
41; see Section 3 in the SM for details of methods and a description of the
differencesbetweenthesetwomethods.Eachtypeofsensitivityanalysisenabledusto
identify the model parameters that had the greatest influence on the predicted
outcomes (i.e., the key parameters). Both analyses identified the same parameters as
being important (see Table 2 and S10 in the SM). Once the key parameters had been
identified, we constructed nonlinear response hypersurfaces based on linear and
interaction terms; we calculated SRCs with their 95% confidence intervals as a
measure of sensitivity (see Table S10 in the SM). Each response hypersurface shows
the quantitative effect of two of the key parameters on the epidemiologic outcome
variable of interest.
SincewewantedtoassesstheeffectsofPrEPinterventionsforbothTDF-basedand
Truvada-based PrEP we conducted four sensitivity analyses: PRCCs for TDF-based
PrEP, response hypersurface modeling for TDF-based PrEP, PRCCs for Truvada-
based PrEP and response hypersurface modeling for Truvada-based PrEP.
1. AVAC. Table of Ongoing and Completed PrEP trials. (2011). Available at http://
www.avac.org/ht/d/sp/i/3507/pid/3507 (accessed on 11/07/2011).
2. Paxton,L.A.,Hope,T.&Jaffe,H.W.Pre-exposureprophylaxisforHIVinfection:
what if it works? Lancet 370, 89–93 (2007).
3. Hillier, S. Pre-Exposure Prophylaxis: Could It Work? Conference on Retroviruses
and Opportunistic Infections (2009).
4. Grant, R. M. et al. Preexposure Chemoprophylaxis for HIV Prevention in Men
Who Have Sex with Men. N Engl J Med (2010).
5. Baeten, J. & Celum, C. Antiretroviral pre-exposure prophylaxis for HIV-1
prevention among heterosexual African men and women: the Partners PrEP
Study. 6th IAS Conference on HIV Pathogenesis Treatment and Prevention.
Abstract #MOAX0106. Rome, Italy (2011).
6. Thigpen, M. C. et al. Daily oral antiretroviral use for the prevention of HIV
infection in heterosexually active young adults in Botswana: results from the
TDF2 study. 6th IAS Conference on HIV Pathogenesis Treatment and Prevention.
Abstract #WELBC01. Rome, Italy (2011).
7. Hurt, C. B., Eron, J. J., Jr. & Cohen, M. S. Pre-Exposure Prophylaxis and
Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis (2011).
8. Aghokeng,A.F.etal.Scale-upofantiretroviraltreatmentinsub-SaharanAfricais
accompanied by increasing HIV-1 drug resistance mutations in drug-naive
patients. AIDS 25, 2183–2188 (2011).
9. Hamers, R. L. et al. HIV-1 drug resistance in antiretroviral-naive individuals in
sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre
observational study. Lancet Infect Dis 11, 750–759 (2011).
10. Masse, B. R., Boily, M. C., Dimitrov, D. & Desai, K. Efficacy dilution in
randomized placebo-controlled vaginal microbicide trials. Emerg Themes
Epidemiol 6, 5 (2009).
11. Weiss, H. A., Wasserheit, J. N., Barnabas, R. V., Hayes, R. J. & Abu-Raddad, L. J.
Persisting with prevention: the importance of adherence for HIV prevention.
Emerg Themes Epidemiol 5, 8 (2008).
12.FamilyHealth International. FHItoinitiateorderly closureofFEM-PrEP. (2011).
Available at Available at: http://www.fhi.org/en/Research/Projects/FEM-
PrEP.htm (accessed on 11/07/2011).
13. Garcia-Lerma, J. G. et al. Prevention of rectal SHIV transmission in macaques by
daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5,
e28 (2008).
14.Subbarao,S.etal.Chemoprophylaxiswithtenofovirdisoproxilfumarateprovided
partial protection against infection with simian human immunodeficiency virus
in macaques given multiple virus challenges. J Infect Dis 194, 904–911 (2006).
15.VanRompay,K.K.etal.Prophylacticandtherapeuticbenefitsofshort-term9-[2-
(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn
macaques following oral inoculation with simian immunodeficiency virus with
reduced susceptibility to PMPA. J Virol 74, 1767–1774 (2000).
16. Veazey, R. S. et al. Protection of macaques from vaginal SHIV challenge by an
orally delivered CCR5 inhibitor. Nat Med 11, 1293–1294 (2005).
17. Garcia-Lerma, J. G. et al. Intermittent prophylaxis with oral truvada protects
macaques from rectal SHIV infection. Sci Transl Med 2, 14ra14 (2010).
18. Smith, D. et al. Clinical utility of HIV standard genotyping among antiretroviral-
naiveindividuals withunknowndurationofinfection.ClinInfectDis44,456–458
(2007).
19. Verhofstede, C., Wanzeele, F. V., Van Der Gucht, B., De Cabooter, N. & Plum, J.
Interruption of reverse transcriptase inhibitors or a switch from reverse
transcriptase to protease inhibitors resulted in a fast reappearance of virus strains
with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13, 2541–2546
(1999).
20. Devereux, H. L., Youle, M., Johnson, M. A. & Loveday, C. Rapid decline in
detectabilityofHIV-1drugresistance mutations afterstoppingtherapy. AIDS13,
F123–127 (1999).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 185 | DOI: 10.1038/srep00185 1021.Brodard, V.etal.Prevalence ofdetection anddynamics ofselectionandreversion
of K65R mutation in nucleoside reverse transcriptase inhibitor-experienced
patients failing an antiretroviral regimen. J Acquir Immune Defic Syndr 39, 250–
253 (2005).
22.Supervie,V.,Garcia-Lerma,J.G.,Heneine,W.&Blower,S.HIV,transmitteddrug
resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A
107, 12381–12386 (2010).
23.vandeVijver,D.A.,Derdelinckx, I.&Boucher,C.A.Circulating HIVtype1drug
resistancewillhavelimitedimpactontheeffectivenessofpreexposureprophylaxis
among young women in Zimbabwe. J Infect Dis 199, 1310–1317 (2009).
24. Abbas, U. L., Hood, G., Wetzel, A. W. & Mellors, J. W. Factors influencing the
emergence and spread of HIV drug resistance arising from rollout of
antiretroviral pre-exposure prophylaxis (PrEP). PLoS One 6, e18165 (2011).
25.Vissers, D.C.,Voeten,H.A.,Nagelkerke, N.J.,Habbema,J.D.&deVlas,S.J.The
impactofpre-exposureprophylaxis(PrEP)onHIVepidemicsinAfricaandIndia:
a simulation study. PLoS One 3, e2077 (2008).
26. Abbas, U. L., Anderson, R. M. & Mellors, J. W. Potential impact of antiretroviral
chemoprophylaxisonHIV-1transmission inresource-limitedsettings.PLoSOne
2, e875 (2007).
27.Pretorius,C.,Stover,J.,Bollinger,L.,Bacaer,N.&Williams,B.Evaluatingthecost-
effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1
transmission in South Africa. PLoS One 5, e13646 (2010).
28. Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in
plasma donors: implications for diagnosis and staging of primary HIV infection.
AIDS 17, 1871–1879 (2003).
29. Owen, S. M. et al. Alternative algorithms for human immunodeficiency virus
infection diagnosis using tests that are licensed in the United States. J Clin
Microbiol 46, 1588–1595 (2008).
30. Steen, T. W. et al. Two and a half years of routine HIV testing in Botswana.
J Acquir Immune Defic Syndr 44, 484–488 (2007).
31.Mine,M.,Ntsipe,T.,Nkoane,T.,Moyo,S.&Gaolathe,T.EvaluationofDetermine
and UniGold Rapid Test Kits for Serologic Screening of HIV-exposed but
Uninfected Infants under 18 Months of Age in a Modified Testing Algorithm in
Botswana.18
thConferenceonRetrovirusesandOpportunisticInfections.Abstract#
655. Boston, USA (2011).
32. Plate, D. K. Evaluation and implementation of rapid HIV tests: the experience in
11 African countries. AIDS research and human retroviruses 23, 1491–1498
(2007).
33. UNAIDS. 2008 Report on the global AIDS epidemic. (2008. )Available at http://
www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/
2008_Global_report.asp (accessed on 11/07/2011).
34. National AIDS Coordinating Agency (NACA) and Central Statistics Office
(CSO). 2008 Botswana AIDS impact survey III (BAIS III). (2009). Available at
(accessed on 11/07/2011).
35. Ministry of Health in Botswana. The Botswana annual country report on the
national HIV drug resistance prevention and assessment strategy. (2008).
Available at (accessed on 11/07/2011).
36. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in
the health sector. (2008). Available at http://www.who.int/hiv/pub/
2008progressreport/en/index.html (accessed on 11/07/2011).
37. National AIDS Coordination Agency (NACA). HIV/AIDS in Botswana:
Estimated Trends and Implications Based on Surveillance and Modeling.
(October 2008). Available at (accessed on 11/07/2011).
38. Bussmann, H. et al. Five-year outcomes of initial patients treated in Botswana’s
National Antiretroviral Treatment Program. AIDS 22, 2303–2311 (2008).
39.Doualla-Bell,F.etal.Five-yearfollowupofgenotypicresistancepatternsinHIV-1
subtypeCinfectedpatientsinBotswanaafterfailureofthymidineanalogue-based
regimens. J Int AIDS Soc 12, 25 (2009).
40. Ministry of Health in Botswana. Botswana National HIV/AIDS Treatment
Guidelines: 2008 version. (2008). Available at http://www.aidstar-one.com/
botswana_national_hivaids_treatment_guidelines_2008_version (accessed on
11/07/2011).
41. Box, G. E. P. & Draper, N. R. Response surfaces, mixtures, and ridge analyses. 2nd
ed. Hoboken, N.J.: John Wiley (2007).
42. National AIDS Coordinating Agency (NACA) and Central Statistics Office
(CSO). Botswana AIDS Impact Survey II (BAIS II). (2005). Available at
www.unbotswana.org.bw/.../final_popular_report_feb06.pdf (accessed on 11/07/
2011).
43. Quinn, T. C. et al. Viral load and heterosexual transmission of human
immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342,
921–929 (2000).
44. Abdool Karim, S. S. & Baxter, C. Antiretroviral Prophylaxis for the Prevention of
HIV Infection: Future Implementation Challenges. HIV Ther 3, 3–6 (2009).
45.Dyer,J.R.etal.Highlevelsofhumanimmunodeficiencyvirustype1inbloodand
semen of seropositive men in sub-Saharan Africa. J Infect Dis 177, 1742–1746
(1998).
46. Operskalski, E. A. et al. Role of viral load in heterosexual transmission of human
immunodeficiency virus type 1 by blood transfusion recipients. Transfusion
Safety Study Group. Am J Epidemiol 146, 655–661 (1997).
47. Smith, R. J. & Blower, S. M. Could disease-modifying HIV vaccines cause
population-level perversity? Lancet Infect Dis 4, 636–639 (2004).
48. Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1
infection, in Rakai, Uganda. J Infect Dis 191, 1403–1409 (2005).
49. Blower, S. M. & Dowlatabadi, H. Sensitivity and uncertainty analysis of complex
models of disease transmission—An HIV model, as an example. Int Stat Rev 62,
229–243 (1994).
Acknowledgments
All authors thank Brad Wagner, Justin Okano, Agnes Paquet and Colombe Chappey for
helpful discussions, Kellie Swanson for editorial assistance, Walid Heneine and J. Gerardo
Garcia-LermafortheirexpertiseonPrEP,theexpertiseandadviceoftheCommitteeforthe
Clinical Care of HIV/AIDS in the Department of HIV/AIDS Prevention and Care in
Botswana, the Ministry of Health in Botswana for epidemiological data and the Central
Statistics Office in Botswana for demographic data. We gratefully acknowledge NIAID/
NIH (R01 AI041935, R01 AI041935-12S1 and R21 AI086701), the John Simon
Guggenheim Foundation and the African Comprehensive HIV and AIDS Partnership for
financial support. VS is grateful for the financial support of the Sidaction, in the form of a
postdoctoral research fellowship. J.S.K. acknowledges NIAID/NIH (RR024369 and
AI27763). The funders had no role instudy design, data collection and analysis, decisionto
publish, or preparation of the manuscript.
Author contributions
Author Contributions: V.S., S.B., M.B. and J.S.K. designed research; V.S. and M.B.
conducted numerical analyses; V.S., S.B., J.S.K., M.B., G.M., T.M., and L.B. analyzed results
and wrote the paper.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
License: This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
How to cite this article: Supervie, V. et al. Modeling dynamic interactions between
pre-exposure prophylaxis interventions & treatment programs: predicting HIV
transmission & resistance. Sci. Rep. 1, 185; DOI:10.1038/srep00185 (2011).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 185 | DOI: 10.1038/srep00185 11